Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes

Erratum issued to A Randomized Placebo-Controlled Phase 3 Study of Mesenchymal stem cells induced to secrete high levels of neurotrophic factors in Amyotrophic Lateral Sclerosis

Supplemental file with updated graphs from the Erratum – A Randomized Placebo-Controlled Phase 3 Study of Mesenchymal stem cells induced to secrete high levels of neurotrophic factors in Amyotrophic Lateral Sclerosis

A Randomized Placebo-Controlled Phase 3 Study of Mesenchymal stem cells induced to secrete high levels of neurotrophic factors in Amyotrophic Lateral Sclerosis

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis

Therapeutic Benefits of MSC-NTF (NurOwn®) Exosomes in Acute Lung Injury Models

CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial

MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model

Effects of MSC-NTF cells on T and B regulatory cell function in ALS

NurOwn, phase 2, randomized, clinical trial in patients with ALS

Phase 2 Open-Label, Multicenter Study of Repeated Intrathecal Administration of Autologous MSC-NTF cells in Progressive Multiple Sclerosis

Molecular Characterization of VEGF Secretion by MSC-NTF Cells (NurOwn®): Therapeutic Implications in ALS

Modulation of CSF Caspase-3 in MSC-NTF Cells (NurOwn®) in a Phase 2 ALS Study: Correlations with CSF Biomarkers and Clinical Response

A Systematic Review of Enrichment Strategies for Current Clinical Trials in ALS

MicroRNA Changes in the NurOwn^® Phase 2 ALS Randomized Clinical Trial: Relationship to Neuroprotection and Innate Immunity

Modulation of CSF miRNAs in ALS Phase 2 Study Participants Treated With MSC-NTF Cells (NurOwn^®)

NurOwn^® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains

miRNA profiling of NurOwn^®: mesenchymal stem cells secreting neurotrophic factors

Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis

Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism

Concise review: Mesenchymal stem cells in neurodegenerative diseases

Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells

Rare combination of myasthenia and motor neuronopathy, responsive to MSC-NTFstem cell therapy

Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2…

Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington’s disease

Differentiated mesenchymal stem cells for sciatic nerve injury

Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection

Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in…

Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease

Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases

Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s disease

Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging